Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression

International Journal of Cancer

Volumn 138, Issue 8, 2016, Pages 1994-2002

  Kurosaki, Akira ^a,b   Hasegawa, Kosei ^a,b   Kato, Tomomi ^b   Abe, Kenji ^c   Hanaoka, Tatsuya ^a,b   Miyara, Akiko ^b   O'Shannessy, Daniel J ^d   Somers, Elizabeth B ^d   Yasuda, Masanori ^b   Sekino, Tetsuo ^c   Fujiwara, Keiichi ^a,b  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c EIDIA Co Ltd   (Japan)

^d Morphotek Inc   (United States)

Author keywords

diagnostic; folate receptor alpha; FRA; ovarian cancer; serum biomarker

Indexed keywords

CA 125 ANTIGEN; FOLATE RECEPTOR 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NON INVASIVE MEASUREMENT; OVARIECTOMY; OVARY CANCER; OVARY METASTASIS; OVARY TUMOR; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; YOUDEN INDEX; AREA UNDER THE CURVE; BLOOD; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLATE RECEPTOR 1; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84958865194     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29937     Document Type: Article

References (41)

1. American Cancer Society. Cancer facts and figures [ http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index ]. 2015.
2. O'Shannessy DJ, Somers EB, Smale R, et al., Expression of folate receptor-alpha (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol 2013; 32: 258-68.
3. Basal E, Eghbali-Fatourechi GZ, Kalli KR, et al., Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One 2009; 4: e6292.
4. Luo G, Xiao Z, Long J, et al., CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg 2013; 17: 2092-8.
5. Yerushalmi R, Tyldesley S, Kennecke H, et al., Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol 2012; 23: 338-45.
6. Pollan M, Varela G, Torres A, et al., Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer. Int J Cancer 2003; 107: 781-90.
7. Kim DH, Yun HY, Ryu DH, et al., Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients. World J Gastroenterol 2015; 21: 1216-21.
8. Lewis MR, Euscher ED, Deavers MT, et al., Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall. Gynecol Oncol 2007; 105: 395-8.
9. Elnakat H, Ratnam M., Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004; 56: 1067-84.
10. O'Shannessy DB, Somers EB, Palmer LM, et al., Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res 2013; 6: 29-44.
11. Allard JE, Risinger JI, Morrison C, et al., Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol 2007; 107: 52-7.
12. Toffoli G, Russo A, Gallo A, et al., Expression of folate binding protein as a prognostic factor for response to platinum containig chemotherapy and survival in human ovarian cancer. Int J Cancer 1998; 79: 121-6.
13. Yang R, Kolb EA, Qin J, et al., The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 2007; 13: 2557-67.
14. O'Shannessy DJ, Yu G, Smale R, et al., Folate receptor alpha expression in lung cancerdiagnostic and prognostic significance. Oncotarget 2012; 3: 414-25.
15. Bueno R, Appasani K, Mercer H, et al., The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 121: 225-33.
16. Chang K, Pastan I., Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1995; 93: 136-40.
17. Vergote IB, Marth C, Coleman RL., Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev 2015; 34: 41-52.
18. Ebel W, Routhier EL, Foley B, et al., Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing receptor alpha. Cancer Immunity 2007; 7: 6-13.
19. Armstrong DK, White AJ, Weil SC, et al., Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 2013; 129: 452-8.
20. Leamon CP, Reddy JA, Vlahov IR, et al., Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007; 121: 1585-92.
21. Reddy JA, Dorton R, Westrick E, et al., Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007; 67: 4434-42.
22. Reddy JA, Xu L-C, Parker NB, et al., Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004; 45: 857-66.
23. Sasaki Y, Miwa K, Yamashita K, et al., A phase I study of farletuzumab, a humanized anti-folate receptor alpha monoclonal antibody, in patients with solid tumors. Invest New Drugs 2015; 33: 332-40.
24. Hasegawa K, Nakamura T, Harvey M, et al., The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 2006; 12: 6170-8.
25. Ab O, Whiteman KR, Bartle LM, et al., IMGN853, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, exhibits potent targeted anti-tumor activity against FRalpha-expressing tumors. Mol Cancer Ther 2015; 14: 1605-13.
26. Naumann RW, Coleman RL, Burger RA, et al., PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013; 31: 4400-6.
27. Morris RT, Joyrich RN, Naumann RW, et al., Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). Ann Oncol 2014; 25: 852-8.
28. Kelemen LE, Brenton JD, Parkinson C, et al., Conditions associated with circulating tumor-associated folate receptor 1 protein in healthy men and women. PLoS One 2014; 9: e96542.
29. O'Shannessy DJ, Somers EB, Albone E, et al., Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget 2011; 2: 1227-43.
30. Youden WJ., Index for rating diagnostic tests. Cancer 1950; 3: 32-5.
31. Cannistra SA., Cancer of the ovary. N Engl J Med 2009; 351: 2519-29.
32. Leung F, Dimitromanolakis A, Kobayashi H, et al., Folate-receptor 1 (FOLR1) protein is elevated in the serum of o varian cancer patients. Clin Biochem 2013; 46: 1462-8.
33. Kew F, Galaal K, Bryant A, et al., Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev 2011; CD006119.
34. Ghaemmaghami F, Karimi Zarchi M, Hamedi B., High levels of CA125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review. Arch Gynecol Obstet 2007; 276: 559-61.
35. Wu TT, Coakley FV, Qayyum A, et al,. Magnetic resonance imaging of ovarian cancer arising in endometriomas. J Comput Assist Tomogr 2004; 28: 836-8.
36. Tanaka YO, Okada S, Yagi T, et al., MRI of endometriotic cysts in association with ovarian carcinoma. Am J Roentgenol 2010; 194: 355-61.
37. Kinkel K, Frei KA, Balleyguier C, et al., Diagnosis of endometriosis with imaging: a review. Eur Radiol 2006; 16: 285-98.
38. Ge J, Zuo C, Guan Y, et al., Increased 18F-FDG uptake of widespread endometriosis mimicking ovarian malignancy. Clin Nucl Med 2015; 40: 186-8.
39. Jeffry L, Kerrou K, Camatte S, et al., Endometriosis with FDG uptake on PET. Eur J Obstet Gynecol Reprod Biol 2004; 117: 236-9.
40. Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer [News Release]. Tokyo, Japan: Eisai Co., Ltd. 11 January 2013. http://www.eisai.com/news/news201305.html (last accessed on 8 October 2014).
41. Vergote I, Armstrong D,. Phase 3 double-blind, placebo-controlled study of weekly farletuzumab with carboplatin/taxane in subjects with platinum sensitive ovarian cancer in first relapse. Int J Gynecol Cancer 2013; 23 (8 suppl): 11.